Tirzepatide is a dual GIP and GLP-1 receptor agonist that has accumulated one of the most substantial research literature bases of any metabolic peptide in recent years. It provides researchers with a well-documented dual incretin model.
Compound Details:
— Compound: Tirzepatide (LY3298176)
— Receptor Targets: GLP-1R, GIPR
— Vial Content: 30mg
— Form: Lyophilized powder
Tirzepatide is studied for its simultaneous activity at both GIP and GLP-1 receptors, a dual engagement that distinguishes it from single receptor agonist models. Research has focused on its influence on insulin secretion modeling, appetite signaling pathways, and energy metabolism research. Its position as one of the most extensively studied incretin-based compounds makes it a reference model for researchers comparing single versus dual receptor engagement within metabolic biology research programs.
Supplied lyophilized in a sterile sealed vial. Third-party tested for identity and purity prior to release. Not for human consumption. For research use only.
Reviews
There are no reviews yet.